CCND1 as a Predictive Biomarker of Neoadjuvant Chemotherapy in Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma 英文参考文献.docVIP

下载本文档

7
0
约3.55万字
约 8页
2017-05-11 发布于上海
举报
版权申诉

CCND1 as a Predictive Biomarker of Neoadjuvant Chemotherapy in Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma 英文参考文献.doc

1、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。。
2、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
4、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
5、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
6、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
7、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

CCND1 as a Predictive Biomarker of Neoadjuvant Chemotherapy in Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma 英文参考文献

CCND1asaPredictiveBiomarkerofNeoadjuvant ChemotherapyinPatientswithLocallyAdvancedHead andNeckSquamousCellCarcinoma ZhienFeng1,2.,WeiGuo1.,ChenpingZhang1,2,QinXu1,2,PingZhang1,2,JianSun1,HanguangZhu1, ZhongheWang1,JiangLi2,3,LizhenWang2,3,BingshunWang4,GuoxinRen1,TongJi1,WenyongTu1, XihuYang1,2,WeiliuQiu1,2,LiMao2,5,ZhiyuanZhang1,2*,WantaoChen1,2 * 1DepartmentofOralandMaxillofacialSurgery,ShanghaiJiaoTongUniversitySchoolofMedicine,NinthPeople’sHospital,Shanghai,China,2ShanghaiKeyLaboratory of Stomatology, Shanghai, China, 3Department of Oral Pathology, Shanghai Jiao Tong University School of Medicine, Ninth People’s Hospital, Shanghai, China, 4DepartmentofBiostatistics,InstituteofMedicalScience,ShanghaiJiaoTongUniversitySchoolofMedicine,Shanghai,China,5DepartmentofOncologyandDiagnostic Sciences,UniversityofMarylandDentalSchool,Baltimore,Maryland,UnitedStatesofAmerica Abstract Background:CyclinD1(CCND1)hasbeenassociatedwithchemotherapyresistanceandpoorprognosis.Inthisstudy,we testedthehypothesisthatCCND1expressiondeterminesresponseandclinicaloutcomesinlocallyadvancedheadandneck squamouscellcarcinoma(HNSCC)patientstreatedwithneoadjuvantchemotherapyfollowedbysurgeryandradiotherapy. MethodologyandFindings:224patientswithHNSCCweretreatedwitheithercisplatin-basedchemotherapyfollowedby surgery and radiotherapy (neoadjuvant group, n=100) or surgery and radiotherapy (non-neoadjuvant group, n=124). CCND1 expression was assessed by immunohistochemistry. CCND1 levels were analyzed with chemotherapy response, disease-free survival (DFS) andoverall survival (OS).There was no significant difference between theneoadjuvant group and non-neoadjuvant group in DFS and OS (p=0.929 and p=0.760) when patients treated with the indiscriminate administrationofcisplatin-basedchemotherapy.However,intheneoadjuvantgroup,patientswhosetumorsshowedalow CCND1expressionmorelikelyrespondtochemotherapy(p,0.001)andhadasignificantlybetterOSandDFSthanthose whosetumorsshowedahighCCND1expression(73%vs8%,p